Ioannis Sarropoulos

1 month ago | nature.com | Piyush Joshi |Anne Rademacher |Michele Bortolomeazzi |Jan-Philipp Mallm |Mari Sepp |Ioannis Sarropoulos | +12 more

AbstractDespite recent advances in understanding disease biology, treatment of group 3/4 medulloblastoma remains a therapeutic challenge in paediatric neuro-oncology1. Bulk-omics approaches have identified considerable intertumoural heterogeneity in group 3/4 medulloblastoma, including the presence of clear single-gene oncogenic drivers in only a subset of cases, whereas in most cases, large-scale copy number aberrations prevail2,3.